Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control
The chronic liver diseases will slowly develop into liver fibrosis, cirrhosis, and even liver cancer if no proper control is performed with high efficiency. Up to now, the most effective treatment for end-stage liver diseases is liver transplantation. However, liver transplantation has the problems...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2022/1526217 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567490244247552 |
|---|---|
| author | Yun Gao Xiushan Yin Xiaomeng Ren |
| author_facet | Yun Gao Xiushan Yin Xiaomeng Ren |
| author_sort | Yun Gao |
| collection | DOAJ |
| description | The chronic liver diseases will slowly develop into liver fibrosis, cirrhosis, and even liver cancer if no proper control is performed with high efficiency. Up to now, the most effective treatment for end-stage liver diseases is liver transplantation. However, liver transplantation has the problems of donor deficiency, low matching rate, surgical complications, high cost, and immune rejection. These problems indicate that novel therapeutic strategies are urgently required. Mesenchymal stem cells (MSCs) are somatic stem cells with multidirectional differentiation potential and self-renewal ability. MSCs can secrete a large number of cytokines, chemokines, immunomodulatory molecules, and hepatotrophic factors, as well as produce extracellular vesicles. They alleviate liver diseases by differentiating to hepatocyte-like cells, immunomodulation, homing to the injured site, regulating cell ferroptosis, regulating cell autophagy, paracrine effects, and MSC-mitochondrial transfer. In this review, we focus on the main resources of MSCs, underlying therapeutic mechanisms, clinical applications, and efforts made to improve MSC-based cell therapy efficiency. |
| format | Article |
| id | doaj-art-028d960dd26c4715adcc2e205966bb7f |
| institution | Kabale University |
| issn | 1687-9678 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-028d960dd26c4715adcc2e205966bb7f2025-02-03T01:01:21ZengWileyStem Cells International1687-96782022-01-01202210.1155/2022/1526217Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease ControlYun Gao0Xiushan Yin1Xiaomeng Ren2Applied Biology LaboratoryApplied Biology LaboratoryApplied Biology LaboratoryThe chronic liver diseases will slowly develop into liver fibrosis, cirrhosis, and even liver cancer if no proper control is performed with high efficiency. Up to now, the most effective treatment for end-stage liver diseases is liver transplantation. However, liver transplantation has the problems of donor deficiency, low matching rate, surgical complications, high cost, and immune rejection. These problems indicate that novel therapeutic strategies are urgently required. Mesenchymal stem cells (MSCs) are somatic stem cells with multidirectional differentiation potential and self-renewal ability. MSCs can secrete a large number of cytokines, chemokines, immunomodulatory molecules, and hepatotrophic factors, as well as produce extracellular vesicles. They alleviate liver diseases by differentiating to hepatocyte-like cells, immunomodulation, homing to the injured site, regulating cell ferroptosis, regulating cell autophagy, paracrine effects, and MSC-mitochondrial transfer. In this review, we focus on the main resources of MSCs, underlying therapeutic mechanisms, clinical applications, and efforts made to improve MSC-based cell therapy efficiency.http://dx.doi.org/10.1155/2022/1526217 |
| spellingShingle | Yun Gao Xiushan Yin Xiaomeng Ren Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control Stem Cells International |
| title | Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control |
| title_full | Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control |
| title_fullStr | Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control |
| title_full_unstemmed | Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control |
| title_short | Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control |
| title_sort | advance of mesenchymal stem cells in chronic end stage liver disease control |
| url | http://dx.doi.org/10.1155/2022/1526217 |
| work_keys_str_mv | AT yungao advanceofmesenchymalstemcellsinchronicendstageliverdiseasecontrol AT xiushanyin advanceofmesenchymalstemcellsinchronicendstageliverdiseasecontrol AT xiaomengren advanceofmesenchymalstemcellsinchronicendstageliverdiseasecontrol |